title: Are Antimalarial Hybrid Molecules a Close Reality or a Distant Dream?
abstract: Emergence of drug-resistantPlasmodium falciparumstrains has led to a situation of haste in the scientific and pharmaceutical communities. Hence, all their efforts are redirected toward finding alternative chemotherapeutic agents that are capable of combating multidrug-resistant parasite strains. In light of this situation, scientists have come up with the concept of hybridization of two or more active pharmacophores into a single chemical entity, resulting in "antimalarial hybrids." The approach has been applied widely for generation of lead compounds against deadly diseases such as cancer and AIDS, with a proven potential for use as novel drugs, but is comparatively new in the sphere of antimalarial drug discovery. A sudden surge has been evidenced in the number of studies on the design and synthesis of hybrids for treating malaria and may be regarded as proof of their potential advantages over artemisinin-based combination therapy (ACT). However, it is evident from recent studies that most of the potential advantages of antimalarial hybrids, such as lower toxicity, better pharmacokinetics, and easier formulation, have yet to be realized. A number of questions left unaddressed at present need to be answered before this approach can progress to the late stages of clinical development and prove their worth in the clinic. To the best of our knowledge, this compilation is the first attempt to shed light on the shortcomings that are surfacing as more and more studies on molecular hybridization of the active pharmacophores of known antimalarials are being published.
authors.affiliation: Chemical Biology Laboratory, Department of Chemistry, University of Delhi, Delhi, India.
authors.forename: Drishti
authors.initials: D
authors.lastname: Agarwal
authors.affiliation: Faculty of Life Sciences and Biotechnology, South Asian University, New Delhi, India.
authors.forename: Rinkoo D
authors.initials: RD
authors.lastname: Gupta
authors.affiliation: Chemical Biology Laboratory, Department of Chemistry, University of Delhi, Delhi, India satishpna@gmail.com.
authors.forename: Satish K
authors.initials: SK
authors.lastname: Awasthi
mesh_terms: D000962:Antimalarials / Q000737:chemistry* / Q000627:therapeutic use*; D037621:Artemisinins / Q000737:chemistry* / Q000627:therapeutic use; D002738:Chloroquine / Q000737:chemistry* / Q000627:therapeutic use; D004338:Drug Combinations; D055808:Drug Discovery; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000469:parasitology; D010963:Plasmodium falciparum / Q000187:drug effects*; D011993:Recombinant Fusion Proteins / Q000737:chemistry* / Q000627:therapeutic use*
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D004338:Drug Combinations; D011993:Recombinant Fusion Proteins; D002738:Chloroquine
keywords: antimalarials; combination therapy; covalent bitherapy; hybrids